Skip to content
PoliticalRepoPoliticalRepo

European Union · Question · QUESTION_WRITTEN

E-8-2019-000110

Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

answeredEuropean Union· European Parliament· IT

Introduced

10 January 2019

Last action

28 February 2019 · Answer

Status

answered

Sponsors

—

Subjects

Discovery layer

Source updated

28 February 2019

Official sourceDownload fileView documentsShare

Official titles

Authentic titles published by the source. The stored canonical title is not replaced.

1 official language

  • English

    Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer

Records

Official question E-8-2019-000110 from European Union at European Parliament. Dated 10 January 2019. Status: answered.

Timeline

  1. 10 January 2019

    Written question

    Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

    Source: QUESTION_WRITTEN

  2. 28 February 2019

    Answer

    Source: QUESTION_WRITTEN_ANSWER

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

11 official files

Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

View fileDownload file

This file cannot be previewed here. Use View or Download.

Reading translation

Translate this document into your language. PoliticalRepo does not store a separate copy per EU language.

On-demand whole-document translation with a downloadable PDF (logo + link to the official source). The official file stays authoritative.

  • Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

    QUESTION_WRITTEN · IT · 4 March 2019

    ViewDownloadOpen at official source

  • Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

    QUESTION_WRITTEN · IT · 4 March 2019

    DownloadOpen at official source

    Reading translation

    Translate this document into your language. PoliticalRepo does not store a separate copy per EU language.

    On-demand whole-document translation with a downloadable PDF (logo + link to the official source). The official file stays authoritative.

  • Answer

    QUESTION_WRITTEN_ANSWER · 28 February 2019

    ViewDownloadOpen at official source

    Reading translation

    Translate this document into your language. PoliticalRepo does not store a separate copy per EU language.

    On-demand whole-document translation with a downloadable PDF (logo + link to the official source). The official file stays authoritative.

  • Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer

    QUESTION_WRITTEN · EN · 23 January 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer

    QUESTION_WRITTEN · EN · 23 January 2019

    DownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer

    QUESTION_WRITTEN · EN · 23 January 2019

    DownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer

    QUESTION_WRITTEN · EN · 23 January 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer

    QUESTION_WRITTEN · EN · 23 January 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

    QUESTION_WRITTEN · IT · 23 January 2019

    DownloadOpen at official source

    Reading translation

    Translate this document into your language. PoliticalRepo does not store a separate copy per EU language.

    On-demand whole-document translation with a downloadable PDF (logo + link to the official source). The official file stays authoritative.

  • Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

    QUESTION_WRITTEN · IT · 23 January 2019

    ViewDownloadOpen at official source

    Reading translation

    Translate this document into your language. PoliticalRepo does not store a separate copy per EU language.

    On-demand whole-document translation with a downloadable PDF (logo + link to the official source). The official file stays authoritative.

  • Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico

    QUESTION_WRITTEN · IT · 23 January 2019

    ViewDownloadOpen at official source

    Reading translation

    Translate this document into your language. PoliticalRepo does not store a separate copy per EU language.

    On-demand whole-document translation with a downloadable PDF (logo + link to the official source). The official file stays authoritative.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.